CDT's Key Investment Sarborg Expands Quantum Computing Platform for Drug Development
CDT is trading near its 52-week low of $0.671 (1.4% above the low) on light trading volume (0.3× avg).
Summary
Sarborg Limited, in which CDT Equity Inc. holds a substantial stake, announced the expansion of its Signature Intelligence platform into quantum-assisted coformer selection. This initiative leverages quantum computing and AI to accelerate solid-form development, aiming to create new patentable assets and enhance existing products. This follows CDT's June 18th announcement valuing its Sarborg stake at $127.5 million, which is significantly higher than CDT's own market cap. For CDT, a company facing "substantial doubt about its ability to continue as a going concern" per its April 10-K, this technological advancement by its primary asset is a critical positive development that could bolster its investment value.
At the time of this announcement, CDT was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.67 to $610.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.